Cumberland Pharmaceuticals Inc. — Form 10-Q Summary
Business Context and Reporting Period
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing and commercializing branded prescription products, primarily in hospital acute care and gastroenterology. The filing covers the unaudited quarter and six months ended June 30, 2015, compared with the comparable 2014 periods.
Key Financial Metrics
| Metric | Q2 2015 | Q2 2014 | Six Months 2015 | Six Months 2014 |
|---|---|---|---|---|
| Net revenue | $8.9 million | $9.8 million | $17.6 million | $17.8 million |
| Operating income | $0.7 million | $1.2 million | $0.7 million | $1.6 million |
| Net income attributable to common shareholders | $0.4 million | $0.7 million | $0.5 million | $1.0 million |
| Diluted EPS | $0.02 | $0.04 | $0.03 | $0.06 |
| Net cash from operating activities | Not separately provided | Not separately provided | $4.1 million | $1.8 million |
- Q2 operating margin was approximately 7.6%, compared with 12.5% in the prior-year quarter; six-month operating margin was approximately 3.9%, compared with 9.1%.
- Q2 net margin attributable to common shareholders was approximately 4.6%, compared with 7.4%; six-month net margin was approximately 2.6%, compared with 5.7%.
- Cash, cash equivalents and marketable securities totaled $53.1 million at June 30, 2015, compared with $54.7 million at December 31, 2014.
- Working capital was $56.7 million and the current ratio was 5.9 at June 30, 2015.
- The company had $1.7 million outstanding under its revolving credit facility, with $10.3 million of stated availability. The facility matures June 26, 2017, bears interest at LIBOR plus 1.0% to 2.85% and was subject to compliance with all covenants at quarter-end.
- Total assets were $92.9 million and total liabilities were $14.2 million at June 30, 2015.
Material Changes Versus the Prior Comparable Period
- Q2 revenue declined 8.6%, primarily because of lower Vaprisol, Omeclamox-Pak, Acetadote and Caldolor revenue. Kristalose revenue increased 15.8% and partially offset these declines.
- Six-month revenue declined 1.4%. Kristalose increased $1.3 million and Caldolor increased $0.5 million, while Acetadote decreased $1.5 million and Omeclamox-Pak decreased $0.8 million.
- Acetadote revenue was pressured by generic competition and a temporary packaging-related product shortage. Authorized Generic revenue was $2.3 million for the first six months of 2015, compared with $3.2 million in the prior-year period.
- Caldolor benefited year-to-date from sales and marketing efforts and a temporary shortage of a competing product, but Q2 revenue declined as competing supply resumed. Management expects full-year 2015 Caldolor revenue to grow but anticipates quarterly volatility.
- Six-month research and development expense increased 59.2% to $2.7 million, primarily due to a $1.2 million FDA fee associated with the Caldolor supplemental application and continued Boxaban and Hepatoren studies.
- Six-month amortization expense increased $0.4 million to approximately $1.0 million because of additional product rights, patents and patent-defense costs.
- Operating cash flow increased to $4.1 million from $1.8 million. Cash declined $0.9 million after $2.7 million of intangible-asset additions, $3.4 million of share repurchases, a $1.6 million Vaprisol contingent-consideration payment and $1.7 million of revolver borrowings.
- The company repurchased 503,602 shares for approximately $3.4 million during the first six months and 235,217 shares during the second quarter.
Guidance, Outlook, Risks and Unusual Items
- No quantitative full-year revenue or earnings guidance is provided. Management states that internal cash generation and available revolver capacity are expected to fund internal growth and capital expenditures.
- Management is pursuing growth through existing-brand promotion, product acquisitions, late-stage and early-stage development, international partnerships and the CET pipeline.
- Hepatoren Phase II Type II results indicated tolerability and a potential urine-output signal at higher doses; enrollment of remaining Type I patients was expected to finish by year-end 2015.
- Boxaban Phase II development began for aspirin-exacerbated respiratory disease, with results expected later in 2015.
- A new Caldolor patent was issued in April 2015 and is scheduled to expire in September 2030. The company submitted an sNDA seeking pediatric labeling changes and expected an FDA response in the fourth quarter of 2015.
- The FDA strengthened the class cardiovascular warning for NSAIDs in July 2015. Cumberland stated that it had not observed a cardiovascular side effect in its Caldolor safety database but would update the label.
- Acetadote patents are being challenged by multiple parties, and generic competition is expected to cause further declines in Acetadote and Authorized Generic revenue. The company also has an arbitration proceeding against Mylan involving alleged contractual manufacturing and supply obligations through April 2016.
- Inventory included approximately $2.9 million of cumulative obsolescence and discontinuance reserves, primarily related to Caldolor, at June 30, 2015.
- The company had approximately $43.9 million of unrecognized net operating loss carryforwards from employee option exercises and expects to pay minimal income taxes in 2015 through their utilization.
- Management identifies dependence on product sales, generic and other competition, patent protection, product acquisitions, access to capital, regulatory approvals, clinical development and acquisition integration as significant risks.
Important Facts for Investors to Verify
- Whether Acetadote generic competition and manufacturing transitions produce further declines in branded and Authorized Generic revenue.
- The durability of Kristalose growth and Caldolor’s ability to sustain annual growth despite quarterly buying-pattern volatility and renewed competition.
- Progress, safety data and regulatory outcomes for the Hepatoren, Boxaban and Caldolor pediatric programs.
- The status and potential financial impact of Acetadote patent challenges and the Mylan arbitration.
- Revolver utilization, covenant compliance, interest-rate exposure and the company’s continued ability to fund acquisitions, development programs and share repurchases.
- Actual utilization and cash-tax benefits of the approximately $43.9 million in option-related net operating loss carryforwards.